NasdaqGS - Nasdaq Real Time Price USD
Adaptimmune Therapeutics plc (ADAP)
As of 12:21 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -0.15 | -0.13 | -0.39 | -0.43 |
| Low Estimate | -0.22 | -0.18 | -0.77 | -0.75 |
| High Estimate | -0.04 | -0.04 | -0.04 | -0.1 |
| Year Ago EPS | -0.2 | -0.24 | -0.54 | -0.39 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 9 | 8 | 8 |
| Avg. Estimate | 11.17M | 12.28M | 166.4M | 45.37M |
| Low Estimate | -- | -- | 144.19M | 34.2M |
| High Estimate | 27.2M | 30.7M | 228.6M | 78.18M |
| Year Ago Sales | 7.32M | 231k | 60.28M | 166.4M |
| Sales Growth (year/est) | 52.60% | 5,216.00% | 176.00% | -72.70% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.12 | -0.1 | -0.1 | -0.07 |
| EPS Actual | -0.2 | -0.24 | -0.18 | 0.24 |
| Difference | -0.08 | -0.14 | -0.08 | 0.31 |
| Surprise % | -66.70% | -140.00% | -80.00% | 442.90% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.15 | -0.13 | -0.39 | -0.43 |
| 7 Days Ago | -0.15 | -0.12 | -0.46 | -0.43 |
| 30 Days Ago | -0.15 | -0.12 | -0.46 | -0.43 |
| 60 Days Ago | -0.15 | -0.12 | -0.47 | -0.43 |
| 90 Days Ago | -0.16 | -0.13 | -0.48 | -0.45 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | -- |
| Up Last 30 Days | -- | -- | 1 | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | 1 | -- | -- |
Growth Estimates
| CURRENCY IN USD | ADAP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 25.00% | -- | -- | 4.40% |
| Next Qtr. | 45.80% | -- | -- | 7.80% |
| Current Year | 27.80% | -- | -- | 2.50% |
| Next Year | -10.30% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 1.00% | -- | -- | 11.89% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/13/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/5/2024 |
| Initiated | HC Wainwright & Co.: Buy | 7/30/2024 |
| Initiated | Scotiabank: Sector Outperform | 5/30/2024 |
| Maintains | Mizuho: Buy to Buy | 5/17/2024 |
| Maintains | Barclays: Underweight to Underweight | 8/10/2023 |
Related Tickers
AFMD Affimed N.V.
3.2200
+3.04%
ADCT ADC Therapeutics SA
3.2100
+6.64%
KPTI Karyopharm Therapeutics Inc.
0.8522
+1.79%
CTMX CytomX Therapeutics, Inc.
1.1500
+2.68%
AUTL Autolus Therapeutics plc
4.5050
+5.75%
GLPG Galapagos NV
29.42
+0.27%
IOVA Iovance Biotherapeutics, Inc.
9.54
-0.52%
SLDB Solid Biosciences Inc.
6.84
+3.17%
IMTX Immatics N.V.
9.50
+0.05%
CLLS Cellectis S.A.
1.9400
+2.10%